Blaxill, M., Rogers, T. & Nevison, C. Autism Tsunami: the Impact of Rising Prevalence on the Societal Cost of Autism in the United States. J Autism Dev Disord (2021). https://doi.org/10.1007/s10803-021-05120-7
The cost of ASD in the U.S. is estimated using a forecast model that for the first time accounts for the true historical increase in ASD. Model inputs include ASD prevalence, census population projections, six cost categories, ten age brackets, inflation projections, and three future prevalence scenarios. Future ASD costs increase dramatically: total base-case costs of $223 (175–271) billion/year are estimated in 2020; $589 billion/year in 2030, $1.36 trillion/year in 2040, and $5.54 (4.29–6.78) trillion/year by 2060, with substantial potential savings through ASD prevention. Rising prevalence, the shift from child to adult-dominated costs, the transfer of costs from parents onto government, and the soaring total costs raise pressing policy questions and demand an urgent focus on prevention strategies. Read here: https://doi.org/10.1007/s10803-021-05120-7Operation Warp Speed provided more than $18B in funding Covid vaccine development. The Lancet: Operation Warp Speed: implications for global vaccine security The article below makes it sounds as if the companies had to dip into their kids' piggy banks to produce the products.
Pharmaceutical groups have already made billions from the pandemic. Now they’re hiking prices
Moderna’s chairman is unapologetic about the price of its Covid vaccine. Like Pfizer, its American peer and rival, the Boston-based biotech company has jacked up the price of its jabs as countries race to order booster shots for next year. “This mRNA was not some academic science that suddenly we found ourselves using to make a vaccine,” said Noubar Afeyan, referring to the underlying technology. “There were ten years, over $2 billion of investment and hundreds of scientists working for many years to make all this possible.”
...Albert Bourla, chief executive of Pfizer, is one of the leading figures in the fight against Covid. Bourla, 59, was paid $21 million (£15.2 million) last year and drew attention in November after selling $5.6 million of shares on the same day the drugmaker announced that its Covid vaccine was more than 90 per cent effective in protecting people from transmission of the virus.
...Earlier this year, Pfizer paid the TV channel National Geographic to produce a glowing documentary, Mission Possible: The Race for a Vaccine, which featured interviews with the company’s scientists and its chief executive, Albert Bourla, 59. He explained that he had told scientists there was an “open chequebook, no questions asked”.
Staff were told to begin manufacturing the vaccine before it was clear that it worked, he said.
“Do it all at once and see if it works,” he declared. “If not, it’s only money.”